Lv3
310 积分 2025-02-22 加入
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
1小时前
待确认
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
4小时前
已完结
KEYNOTE-811: pembrolizumab in advanced HER2+ gastric cancer
4小时前
已完结
KEYNOTE-811: pembrolizumab in advanced HER2+ gastric cancer
4小时前
已完结
TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061
19小时前
已完结
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
21小时前
已完结
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
2天前
已完结
Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma
4天前
已完结
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
7天前
已完结
Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis
7天前
已完结
皖公网安备34019202002308
